TG THERAPEUTICS INC (TGTX) Fundamental Analysis & Valuation

NASDAQ:TGTX • US88322Q1085

Current stock price

34.3 USD
-0.3 (-0.87%)
At close:
34.3 USD
0 (0%)
After Hours:

This TGTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. TGTX Profitability Analysis

1.1 Basic Checks

  • TGTX had positive earnings in the past year.
  • In the past year TGTX has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
  • TGTX had a negative operating cash flow in each of the past 5 years.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • The Return On Assets of TGTX (42.06%) is better than 98.64% of its industry peers.
  • The Return On Equity of TGTX (69.01%) is better than 98.84% of its industry peers.
  • With an excellent Return On Invested Capital value of 12.39%, TGTX belongs to the best of the industry, outperforming 94.96% of the companies in the same industry.
Industry RankSector Rank
ROA 42.06%
ROE 69.01%
ROIC 12.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • The Profit Margin of TGTX (72.56%) is better than 98.26% of its industry peers.
  • With an excellent Operating Margin value of 20.01%, TGTX belongs to the best of the industry, outperforming 93.22% of the companies in the same industry.
  • TGTX has a Gross Margin of 83.66%. This is amongst the best in the industry. TGTX outperforms 87.21% of its industry peers.
  • TGTX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 20.01%
PM (TTM) 72.56%
GM 83.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.58%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TGTX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TGTX is creating some value.
  • TGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • TGTX has an Altman-Z score of 8.06. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of TGTX (8.06) is better than 78.29% of its industry peers.
  • A Debt/Equity ratio of 0.38 indicates that TGTX is not too dependend on debt financing.
  • The Debt to Equity ratio of TGTX (0.38) is worse than 70.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 8.06
ROIC/WACC1.31
WACC9.44%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • TGTX has a Current Ratio of 4.10. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TGTX (4.10) is comparable to the rest of the industry.
  • A Quick Ratio of 3.29 indicates that TGTX has no problem at all paying its short term obligations.
  • TGTX has a Quick ratio of 3.29. This is comparable to the rest of the industry: TGTX outperforms 42.05% of its industry peers.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.29
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. TGTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 257.14% over the past year.
  • TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 87.32%.
  • TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 426.73% yearly.
EPS 1Y (TTM)257.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)87.32%
Revenue growth 3Y504.86%
Revenue growth 5Y426.73%
Sales Q2Q%78%

3.2 Future

  • TGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.96% yearly.
  • The Revenue is expected to grow by 25.78% on average over the next years. This is a very strong growth
EPS Next Y195.8%
EPS Next 2Y113.77%
EPS Next 3Y76.82%
EPS Next 5Y52.96%
Revenue Next Year46.23%
Revenue Next 2Y36.11%
Revenue Next 3Y34.1%
Revenue Next 5Y25.78%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. TGTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 68.60, which means the current valuation is very expensive for TGTX.
  • 89.73% of the companies in the same industry are more expensive than TGTX, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.38. TGTX is valued rather expensively when compared to this.
  • Based on the Price/Forward Earnings ratio of 23.19, the valuation of TGTX can be described as rather expensive.
  • TGTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 93.80% of the companies in the same industry.
  • TGTX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 38.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 68.6
Fwd PE 23.19
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaper than 90.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 45.11
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TGTX's earnings are expected to grow with 76.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y113.77%
EPS Next 3Y76.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TGTX Dividend Analysis

5.1 Amount

  • No dividends for TGTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TGTX Fundamentals: All Metrics, Ratios and Statistics

TG THERAPEUTICS INC

NASDAQ:TGTX (4/16/2026, 4:30:02 PM)

After market: 34.3 0 (0%)

34.3

-0.3 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners65.72%
Inst Owner Change0%
Ins Owners7.16%
Ins Owner Change-20.63%
Market Cap5.48B
Revenue(TTM)616.29M
Net Income(TTM)447.18M
Analysts78.67
Price Target45.05 (31.34%)
Short Float %19.52%
Short Ratio15.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-44.81%
Min EPS beat(2)-60.92%
Max EPS beat(2)-28.7%
EPS beat(4)0
Avg EPS beat(4)-49.18%
Min EPS beat(4)-83.83%
Max EPS beat(4)-23.26%
EPS beat(8)2
Avg EPS beat(8)-7.43%
EPS beat(12)5
Avg EPS beat(12)38.02%
EPS beat(16)8
Avg EPS beat(16)30.8%
Revenue beat(2)1
Avg Revenue beat(2)1.2%
Min Revenue beat(2)-1.78%
Max Revenue beat(2)4.19%
Revenue beat(4)2
Avg Revenue beat(4)-0.91%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)4.19%
Revenue beat(8)6
Avg Revenue beat(8)3.3%
Revenue beat(12)9
Avg Revenue beat(12)33.32%
Revenue beat(16)10
Avg Revenue beat(16)24.87%
PT rev (1m)0%
PT rev (3m)-0.27%
EPS NQ rev (1m)-8.09%
EPS NQ rev (3m)-12.65%
EPS NY rev (1m)-8.01%
EPS NY rev (3m)-20.71%
Revenue NQ rev (1m)-0.77%
Revenue NQ rev (3m)0.69%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-0.08%
Valuation
Industry RankSector Rank
PE 68.6
Fwd PE 23.19
P/S 8.89
P/FCF N/A
P/OCF N/A
P/B 8.45
P/tB 8.45
EV/EBITDA 45.11
EPS(TTM)0.5
EY1.46%
EPS(NY)1.48
Fwd EY4.31%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS3.86
BVpS4.06
TBVpS4.06
PEG (NY)0.35
PEG (5Y)N/A
Graham Number6.75665 (-80.3%)
Profitability
Industry RankSector Rank
ROA 42.06%
ROE 69.01%
ROCE 13.56%
ROIC 12.39%
ROICexc 14.68%
ROICexgc 14.68%
OM 20.01%
PM (TTM) 72.56%
GM 83.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.58%
GM growth 5YN/A
F-Score5
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 1.99
Cap/Depr 362.71%
Cap/Sales 0.03%
Interest Coverage 5.09
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.29
Altman-Z 8.06
F-Score5
WACC9.44%
ROIC/WACC1.31
Cap/Depr(3y)142.96%
Cap/Depr(5y)115.14%
Cap/Sales(3y)0.02%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)257.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y195.8%
EPS Next 2Y113.77%
EPS Next 3Y76.82%
EPS Next 5Y52.96%
Revenue 1Y (TTM)87.32%
Revenue growth 3Y504.86%
Revenue growth 5Y426.73%
Sales Q2Q%78%
Revenue Next Year46.23%
Revenue Next 2Y36.11%
Revenue Next 3Y34.1%
Revenue Next 5Y25.78%
EBIT growth 1Y194.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.86%
OCF growth 3YN/A
OCF growth 5YN/A

TG THERAPEUTICS INC / TGTX Fundamental Analysis FAQ

What is the fundamental rating for TGTX stock?

ChartMill assigns a fundamental rating of 5 / 10 to TGTX.


What is the valuation status for TGTX stock?

ChartMill assigns a valuation rating of 5 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.


What is the profitability of TGTX stock?

TG THERAPEUTICS INC (TGTX) has a profitability rating of 5 / 10.


What is the expected EPS growth for TG THERAPEUTICS INC (TGTX) stock?

The Earnings per Share (EPS) of TG THERAPEUTICS INC (TGTX) is expected to grow by 195.8% in the next year.